Targeted Therapies in Ovarian Cancer
Franco M. Muggia, MD, professor of oncology, New York University, director, Division of Medical Oncology, New York University Medical Center, discusses the challenge of developing targeted therapies to treat ovarian cancer.
Franco M. Muggia, MD, professor of oncology, New York University, director, Division of Medical Oncology, New York University Medical Center, discusses the challenge of developing targeted therapies to treat ovarian cancer.
Clinical Pearls:
- There have not been many targeted therapies developed in ovarian cancer
- Physicians still rely on a chemotherapy regimen to treat patients with ovarian cancer
- Although this regimen eliminates advanced disease about 80-90% of the time, the disease eventually comes back
- TargetingBRCAand PARP have proven to be good targets to develop further
Recent Videos
Related Content
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024Article
In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
